# CG Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cg-oncology

- Industry: Biotechnology
- Headquarters: Irvine, US
- Website: www.cgoncology.com/
- Total disclosed funding: $318M
- Latest round: Series F (Aug 2, 2023)
- Investors on record: 18

## About

Based in California, US, and founded in 2010 by co-founders Alex Yeung and Paul DeRidder, MD, CG Oncology, Inc., formerly known as Cold Genesys, Inc., operates as a clinical-stage biopharmaceutical company that develops immunotherapeutic drugs for oncolytic studies for the treatment of patients with advanced cancer. In January 2024, CG Oncology, Inc. raised USD 380 million in an IPO, selling 20 million shares at USD 19 per share, above the expected USD 16–18 range, on the Nasdaq Global Select Market under the ticker symbol "CGON." CG Oncology, Inc. has granted the underwriters a 30-day option to purchase up to an additional 3 million shares of common stock as part of the listing. Ally Bridge Group retained a 3.9% minority stake, Decheng Capital retained a 7.2% minority stake, Foresite Capital retained a 4.4% minority stake, Kissei Pharmaceutical Co., Ltd. retained a 5.6% minority stake, ORI Capital retained a 7.8% minority stake, and TCG Crossover Management retained a 4.4% minority stake in the company, respectively. As of 2024, the company is led by its CEO, Arthur Kuan.


The company provides a wide range of clinical biopharmaceutical products, such as cretostimogene grenadenorepvec, an investigational-engineered oncolytic immunotherapy. This therapy is in clinical trials for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) both as a monotherapy and in combination with other treatments.

## Funding rounds

- Series F, Aug 2, 2023, $105M — Longitude Capital, Foresite Capital, Decheng Capital, BVF Partners, RA Capital Management, Ally Bridge Group, Malin Corporation, Janus Henderson Investors, Acorn Bioventures, Avidity Partners, TCG Crossover Management
- Series E, Sep 30, 2022, $120M — Longitude Capital, Decheng Capital, RA Capital Management, Ally Bridge Group, Malin Corporation, ORI Capital, Sirona Capital, Acorn Bioventures
- Series D, Dec 10, 2020, $47M — Oria Capital, Perseverance Capital, Camford, Kissei Pharmaceutical Co., Ltd.
- Series C, Mar 18, 2019, $22M — ORI Capital, Perseverance Capital
- Series B, Aug 5, 2015, $10M — WI Harper Group, Ally Bridge Group
- Series A, Jul 30, 2014, $14M — Ally Bridge Group

## Investors

- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series A, Series B, Series E, Series F
- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series B
- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series C, Series E
- Perseverance Capital (https://capitalatlas.ai/funds/perseverance-capital) — Series C, Series D
- Oria Capital (https://capitalatlas.ai/funds/oria-capital) — Series D
- Camford (https://capitalatlas.ai/funds/camford) — Series D
- Kissei Pharmaceutical Co., Ltd. — Series D
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series E, Series F
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series E, Series F
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series E, Series F
- Malin Corporation — Series E, Series F
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series E
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series E, Series F
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series F
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series F
- Janus Henderson Investors — Series F
- Avidity Partners — Series F
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series F